Osteoarthritis: Mechanistic Insights, Senescence, and Novel Therapeutic Opportunities

Overview

Journal Bioelectricity

Specialty Biology

Date 2024 Oct 2

PMID 39355566

Authors

Paula Carpintero-Fernandez

Marta Varela-Eirin

Alejandro Garcia-Yuste

Inaki Lopez-Diaz

Jose Ramon Caeiro

Maria D Mayan

Affiliations

Soon will be listed here.

Abstract

Osteoarthritis (OA) is the most common joint disease. In the last years, the research community has focused on understanding the molecular mechanisms that led to the pathogenesis of the disease, trying to identify different molecular and clinical phenotypes along with the discovery of new therapeutic opportunities. Different types of cell-to-cell communication mechanisms have been proposed to contribute to OA progression, including mechanisms mediated by connexin43 (Cx43) channels or by small extracellular vesicles. Furthermore, changes in the chondrocyte phenotype such as cellular senescence have been proposed as new contributors of the OA progression, changing the paradigm of the disease. The use of different drugs able to restore chondrocyte phenotype, to reduce cellular senescence and senescence-associated secretory phenotype components, and to modulate ion channel activity or Cx43 appears to be promising therapeutic strategies for the different types of OA. In this review, we aim to summarize the current knowledge in OA phenotypes related with aging and tissue damage and the new therapeutic opportunities currently available.

References

Tschon M, Contartese D, Pagani S, Borsari V, Fini M . Gender and Sex Are Key Determinants in Osteoarthritis Not Only Confounding Variables. A Systematic Review of Clinical Data. J Clin Med. 2021; 10(14). PMC: 8303951. DOI: 10.3390/jcm10143178. View

Johnson V, Hunter D . The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol. 2014; 28(1):5-15. DOI: 10.1016/j.berh.2014.01.004. View

Vasileiou P, Evangelou K, Vlasis K, Fildisis G, Panayiotidis M, Chronopoulos E . Mitochondrial Homeostasis and Cellular Senescence. Cells. 2019; 8(7). PMC: 6678662. DOI: 10.3390/cells8070686. View

van Spil W, Kubassova O, Boesen M, Bay-Jensen A, Mobasheri A . Osteoarthritis phenotypes and novel therapeutic targets. Biochem Pharmacol. 2019; 165:41-48. DOI: 10.1016/j.bcp.2019.02.037. View

Lindstrom E, Rizoska B, Tunblad K, Edenius C, Bendele A, Maul D . The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. J Transl Med. 2018; 16(1):56. PMC: 5845353. DOI: 10.1186/s12967-018-1425-7. View

Krzeski P, Buckland-Wright C, Balint G, Cline G, Stoner K, Lyon R . Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007; 9(5):R109. PMC: 2212568. DOI: 10.1186/ar2315. View

Nogueira-Recalde U, Lorenzo-Gomez I, Blanco F, Loza M, Grassi D, Shirinsky V . Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine. 2019; 45:588-605. PMC: 6642320. DOI: 10.1016/j.ebiom.2019.06.049. View

Hermann W, Lambova S, Muller-Ladner U . Current Treatment Options for Osteoarthritis. Curr Rheumatol Rev. 2017; 14(2):108-116. DOI: 10.2174/1573397113666170829155149. View

Carpintero-Fernandez P, Gago-Fuentes R, Wang H, Fonseca E, Caeiro J, Valiunas V . Intercellular communication via gap junction channels between chondrocytes and bone cells. Biochim Biophys Acta Biomembr. 2018; 1860(12):2499-2505. PMC: 6203615. DOI: 10.1016/j.bbamem.2018.09.009. View

10.

Fleischmann R, Bliddal H, Blanco F, Schnitzer T, Peterfy C, Chen S . A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol. 2019; 71(7):1056-1069. DOI: 10.1002/art.40840. View

11.

Huang X, Ni B, Xi Y, Chu X, Zhang R, You H . Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis. Aging (Albany NY). 2019; 11(24):12532-12545. PMC: 6949101. DOI: 10.18632/aging.102586. View

12.

Cucchiarini M, de Girolamo L, Filardo G, Oliveira J, Orth P, Pape D . Basic science of osteoarthritis. J Exp Orthop. 2016; 3(1):22. PMC: 5021646. DOI: 10.1186/s40634-016-0060-6. View

13.

Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View

14.

Donahue H, Qu R, Genetos D . Joint diseases: from connexins to gap junctions. Nat Rev Rheumatol. 2017; 14(1):42-51. DOI: 10.1038/nrrheum.2017.204. View

15.

Ansari M, Ahmad N, Voleti S, Wase S, Novak K, Haqqi T . Mitochondrial dysfunction triggers a catabolic response in chondrocytes via ROS-mediated activation of the JNK/AP1 pathway. J Cell Sci. 2020; 133(22). PMC: 7725611. DOI: 10.1242/jcs.247353. View

16.

Oo W, Little C, Duong V, Hunter D . The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. Drug Des Devel Ther. 2021; 15:2921-2945. PMC: 8273751. DOI: 10.2147/DDDT.S295224. View

17.

Gao S, Zeng C, Li L, Luo W, Zhang F, Tian J . Correlation between senescence-associated beta-galactosidase expression in articular cartilage and disease severity of patients with knee osteoarthritis. Int J Rheum Dis. 2015; 19(3):226-32. DOI: 10.1111/1756-185X.12096. View

18.

Gomez R, Conde J, Scotece M, Gomez-Reino J, Lago F, Gualillo O . What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol. 2011; 7(9):528-36. DOI: 10.1038/nrrheum.2011.107. View

19.

Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton J . Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017; 5:16044. PMC: 5240031. DOI: 10.1038/boneres.2016.44. View

20.

Gillam M, Lie S, Salter A, Furnes O, Graves S, Havelin L . The progression of end-stage osteoarthritis: analysis of data from the Australian and Norwegian joint replacement registries using a multi-state model. Osteoarthritis Cartilage. 2013; 21(3):405-12. DOI: 10.1016/j.joca.2012.12.008. View